Bioequivalence Study of GZR18 Injection Before and After CMC Change — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Bioequivalence Study of GZR18 Injection Before and After CMC Change — Stella

Recruiting

Back to Obesity&T2D trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

The Second Affiliated Hospital of Soochow University, Suzhou, Suzhou

Key details

Phase

Early testing

Sponsor

Gan & Lee Pharmaceuticals.

Enrollment target

~138 participants

Started

January 2026

Primary completion

May 2026

Age range

18 Years – 50 Years

Sex

Male only

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov